Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Anja H. Loos
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Sorafenib in Combination With Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-Line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Clinical Cancer Research
Cancer Research
Oncology
Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
Farmeconomia. Health economics and therapeutic pathways
Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Oxaliplatin With Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFOX 4) as First-Line Therapy for Patients With Metastatic Colorectal Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
JAMA - Journal of the American Medical Association
Medicine
Oxaliplatin, 5-Fluorouracil and Leucovorin (Modified FOLFOX-6) as First-Line Chemotherapy for Advanced Gastric Cancer Patients With Poor Performance Status
Oncology Letters
Cancer Research
Oncology
"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study
BMC Cancer
Cancer Research
Oncology
Genetics
Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study
British Journal of Cancer
Cancer Research
Oncology
Serum Iron Levels as a New Biomarker in Chemotherapy With Leucovorin and Fluorouracil Plus Oxaliplatin or Leucovorin and Fluorouracil Plus Irinotecan, With or Without Molecularly-Targeted Drugs
Molecular and Clinical Oncology
Cancer Research
Oncology
